In another study that recruited locally recurrent or metastatic HER2+ breast cancer patients, the effectiveness and safety of pertuzumab and trastuzumab joined with a taxane (docetaxel, paclitaxel, or nab-paclitaxel) at investigator choice were the main endpoints. This evidence concerns the gene ERBB2 and breast carcinoma.